Clinical trials: Hematologic Tests
Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia (APL)
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
This clinical study will demonstrate the accuracy of the chromosomal aberration and gene mutation markers of the AMLProfiler molecular diagnostic assay and generate clinical performance data to support a Pre-Market Approval (PMA)…
- Conditions
- Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia (APL), Refractory Anemia With Excess of Blasts (RAEB)
- Trial name
- NCT01463410
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 264 people
- Sponsor
- Skyline Diagnostics BV
Healthy, Anemia
Noninvasive Hemoglobin Testing, Prospective Blood Donors
The objective of this clinical investigation is to evaluate the pulse oximeter devices for screening prospective blood donors. The purpose study is to report on the accuracy of noninvasive hemoglobin (SpHb) as compared to…
- Trial name
- NCT04450381
- Testing
- Rad-67 Pulse oximeter & DCI Mini sensor
- Where
- United States
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Masimo Corporation
Red-Cell Aplasia, Pure, Chronic Renal Failure
Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another Erythropoietin
The purpose of this study is to assess the incidence of pure red cell aplasia (PRCA [suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production]) among participants with chronic renal failure…
- Trial name
- NCT00210951
- Testing
- No Intervention
- Volunteers
- 4,761 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Thoracic Cancer, Ovarian Cancer
Project CADENCE (CAncer Detected Early caN be CurEd)
With existing evidence showing the difference in miRNA expression levels between non-cancer and cancer groups, the investigators assume that levels of DNA methylation, RNA expression as well as protein concentration will also be…
- Conditions
- Thoracic Cancer, Ovarian Cancer, Liver Cancer, Prostate Cancer
- Trial name
- CADENCE (NCT05633342)
- Where
- Singapore
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- MiRXES Pte Ltd
Healthy, Blood Cell Count
Blood Testing at Entia
The investigators are recruiting healthy volunteers to donate 1-5 (depending on study visits. and donors will be notified upon invitation) finger prick blood samples or venous samples to Entia for the further development and…
- Trial name
- NCT05580055
- Testing
- Affinity
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Entia Ltd
Colon Cancer
OctavaColon Cancer Blood Tests OctavaGold and OctavaSilver - Blood Tests for the Help in Diagnosis of Colon Cancer Clinical Study Protocol
The OctavaColon tests are qualitative plasma tests that are indicated to people above 18 years of age suspected with colon abnormality.
- Trial name
- NCT02066259
- Where
- 3 sites in Israel
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- Eventus Diagnostics Ltd
Hemophilia A
Study Evaluating ReFacto in Hemophilia A
To identify the causative mutations in previously untreated patients with hemophilia A enrolled in the ReFacto® clinical safety and efficacy study CTN 93-R833-0XX/C9741-28, using two established hemophilia mutation testing…
- Trial name
- NCT00038909
- Testing
- BDDrFVII
- Volunteers
- 103 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hemophilia A
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"
In this study researchers want to gather more information about safety and effectiveness of BAY 2599023 (DTX201), a drug therapy that delivers the human factor VIII gene into the human body by use of a viral vector to treat the…
- Trial name
- NCT03588299
- Testing
- BAY2599023 (DTX201)
- Where
- 13 sites in United States, Bulgaria and 4 more
- Volunteers
- 11 people
- Sponsor
- Bayer
Abnormalities in the Blood Test Results
Assessment of Accuracy and Safety of LabTest Checker
The goal of this study is to assess performance of a new clinical decision support system named LabTest Checker in a cohort of adult patients reporting to the internal ward's emergency department.
- Trial name
- LTC-AI (NCT05813938)
- Testing
- LabTest Checker
- Where
- Poland
- Volunteers
- 101 people
- Sponsor
- Labplus Sp. z o.o.
Multiple Myeloma
Improving the Quality of Multiple Myeloma Treatment With Patient Care Plans
The overarching objective of this study is to evaluate the symptom assessment and management behaviors used by multiple myeloma (MM) providers for alignment with evidence-based practices, and to explore changes in these symptom…
- Trial name
- NCT03046329
- Testing
- Carevive CPS
- Volunteers
- 90 people
- Sponsor
- Carevive Systems, Inc.
Healthy Volunteers
Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants
This study is researching experimental drugs called REGN9933 and REGN7508 (called "study drugs") and comparing their effects to approved treatments of rivaroxaban and aspirin (called "standard treatments").
- Trial name
- NCT06444178
- Testing
- Aspirin, REGN9933, REGN7508
- Where
- United Kingdom
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Hemophilia A
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
This is an exploratory, single group, Phase 4, study to assess treatment with fitusiran prophylaxis after switching from emicizumab prophylaxis.
- Trial name
- NCT06145373
- Testing
- Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 20 people
- Sponsor
- Sanofi